Goldman Sachs
ZYNE

Goldman Sachs’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Goldman Sachs’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-33,600
Closed -$570K – 6925
2017
Q2 		$570K Hold
33,600
– – ﹤0.01% 4983
2017
Q1 		$675K Buy
+33,600
New +$668K ﹤0.01% 4737

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Goldman Sachs's ZYNE Position: Q4 2022 in Review

Goldman Sachs sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 11,344 shares — an estimated $8K sold.

Goldman Sachs first reported a position in ZYNE in Q1 2017 and held it in 19 quarters. The position peaked at $1.63M in Q1 2017. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Goldman Sachs reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 11,344 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $8K.
  • Goldman Sachs first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 19 quarters.
  • Goldman Sachs's Zynerba Pharmaceuticals, Inc position peaked at $1.63M in Q1 2017.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.